Hudson Bay Capital Management’s Veraxa Biotech AG Warrants VRXAW Stock Holding History

Hudson Bay Capital Management’s Portfolio VRXAW Stock Details VRXAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11K	Buy	+100,000	New	+$17.6K	﹤0.01%	1314

Other funds holding VRXAW

CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return

AIMCA

Alberta Investment Management Corp (AIMCo) Edmonton, Alberta, Canada $17.9B AUM 27.56% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Whitebox Advisors Minneapolis, Minnesota $7.65B AUM 13.87% 1-Year Est. Return

Hudson Bay Capital Management's VRXAW Position: Q2 2026 in Review

Hudson Bay Capital Management opened a new position in Veraxa Biotech AG Warrants (VRXAW) in Q2 2026: 100,000 shares worth $11K. The stake represents ﹤0.01% of the portfolio and ranks #1314 among its holdings.

26 funds tracked by Wall St. Rank hold VRXAW as of Q2 2026.

Hudson Bay Capital Management held 100,000 shares of Veraxa Biotech AG Warrants worth $11K as of Q2 2026.
Veraxa Biotech AG Warrants was a new Hudson Bay Capital Management position in Q2 2026.
Veraxa Biotech AG Warrants made up ﹤0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #1314 holding.
26 funds tracked by Wall St. Rank held Veraxa Biotech AG Warrants as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.